Suppr超能文献

α1-抗胰蛋白酶缺乏症患者死亡率的预测因素

Predictors of mortality in alpha1-antitrypsin deficiency.

作者信息

Dawkins P A, Dowson L J, Guest P J, Stockley R A

机构信息

Lung Investigation Unit, Queen Elizabeth Hospital, Birmingham, UK.

出版信息

Thorax. 2003 Dec;58(12):1020-6. doi: 10.1136/thorax.58.12.1020.

Abstract

BACKGROUND

Lung density measurements by computed tomography have previously been found to be a more sensitive indicator of disease progression in emphysema of alpha(1)-antitrypsin deficiency than lung function measurements. The aim of this study was to investigate the predictive potential of several parameters, including CT scanning, for mortality in patients with severe alpha(1)-antitrypsin deficiency.

METHODS

Over a 5 year period, 256 patients with alpha(1)-antitrypsin deficiency (PiZ phenotype) were assessed, of whom 254 underwent lung function testing and 197 had thoracic CT scans. Lung function, CT scans, health status (St George's Respiratory Questionnaire, SGRQ), and other clinical data of survivors and non-survivors were compared and these parameters were applied to survival analyses.

RESULTS

There were 22 deaths in this patient cohort, 10 of which were classified as "respiratory" deaths. Baseline lung function parameters (forced expiratory volume in 1 second (FEV(1)), carbon monoxide transfer coefficient (KCO)), and CT scores were significantly lower in the non-survivors than in the survivors. 170 of the 256 patients had complete data for entry into multiple regression analyses (Cox proportional hazards model). In the univariate analysis, upper zone expiratory scan had the best association with all cause (p = 0.001) and respiratory mortality (p<0.001), whereas FEV(1) (p = 0.158 all cause, 0.015 respiratory) and KCO (p = 0.002 all cause, 0.012 respiratory) had poorer associations with mortality. Only age gave further independent predictive information regarding all cause or respiratory mortality when the CT scan was entered into the survival analyses.

CONCLUSIONS

CT scanning predicts respiratory and all cause mortality in alpha(1)-antitrypsin deficiency and appears to be superior to lung function parameters, especially FEV(1).

摘要

背景

既往研究发现,对于α1-抗胰蛋白酶缺乏所致肺气肿,通过计算机断层扫描测量肺密度是比肺功能测量更敏感的疾病进展指标。本研究旨在调查包括CT扫描在内的多个参数对重度α1-抗胰蛋白酶缺乏患者死亡率的预测潜力。

方法

在5年期间,对256例α1-抗胰蛋白酶缺乏(PiZ表型)患者进行评估,其中254例接受了肺功能测试,197例进行了胸部CT扫描。对幸存者和非幸存者的肺功能、CT扫描、健康状况(圣乔治呼吸问卷,SGRQ)及其他临床数据进行比较,并将这些参数应用于生存分析。

结果

该患者队列中有22例死亡,其中10例被归类为“呼吸性”死亡。非幸存者的基线肺功能参数(第1秒用力呼气量(FEV1)、一氧化碳转运系数(KCO))和CT评分显著低于幸存者。256例患者中有170例具有完整数据可纳入多元回归分析(Cox比例风险模型)。在单因素分析中,上叶呼气扫描与全因死亡率(p = 0.001)和呼吸性死亡率(p<0.001)的相关性最佳,而FEV1(全因死亡率p = 0.158,呼吸性死亡率p = 0.015)和KCO(全因死亡率p = 0.002,呼吸性死亡率p = 0.012)与死亡率的相关性较差。当将CT扫描纳入生存分析时,只有年龄提供了关于全因或呼吸性死亡率的进一步独立预测信息。

结论

CT扫描可预测α1-抗胰蛋白酶缺乏患者的呼吸性和全因死亡率,且似乎优于肺功能参数,尤其是FEV1。

相似文献

1
Predictors of mortality in alpha1-antitrypsin deficiency.
Thorax. 2003 Dec;58(12):1020-6. doi: 10.1136/thorax.58.12.1020.
4
Mortality in alpha-1-antitrypsin deficiency in the United Kingdom.
Respir Med. 2009 Oct;103(10):1540-7. doi: 10.1016/j.rmed.2009.04.004. Epub 2009 May 13.
5
Lung density associates with survival in alpha 1 antitrypsin deficient patients.
Respir Med. 2016 Mar;112:81-7. doi: 10.1016/j.rmed.2016.01.007. Epub 2016 Jan 22.
8
Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.
Eur Respir J. 2009 Jun;33(6):1338-44. doi: 10.1183/09031936.00061208. Epub 2009 Jan 22.

引用本文的文献

1
The Use of CT Densitometry for the Assessment of Emphysema in Clinical Trials: A Position Paper from the Fleischner Society.
Am J Respir Crit Care Med. 2025 Mar 24;211(5):709-28. doi: 10.1164/rccm.202410-2012SO.
2
Antitrypsin deficiency: still more to learn about the lung after 60 years.
ERJ Open Res. 2024 Jul 22;10(4). doi: 10.1183/23120541.00139-2024. eCollection 2024 Jul.
3
Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews.
Eur Respir Rev. 2022 Mar 23;31(163). doi: 10.1183/16000617.0262-2021. Print 2022 Mar 31.
4
Imaging in alpha-1 antitrypsin deficiency: a window into the disease.
Ther Adv Chronic Dis. 2021 Jul 29;12_suppl:20406223211024523. doi: 10.1177/20406223211024523. eCollection 2021.
5
Gene coexpression networks reveal novel molecular endotypes in alpha-1 antitrypsin deficiency.
Thorax. 2021 Feb;76(2):134-143. doi: 10.1136/thoraxjnl-2019-214301. Epub 2020 Dec 10.
6
Feasibility of Aerosolized Alpha-1 Antitrypsin as a Therapeutic Option.
Chronic Obstr Pulm Dis. 2020 Jul;7(3):272-279. doi: 10.15326/jcopdf.7.3.2019.0179.
7
Advances in Alpha-1 Antitrypsin Gene Therapy.
Am J Respir Cell Mol Biol. 2020 Nov;63(5):560-570. doi: 10.1165/rcmb.2020-0159PS.
9
New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency.
Int J Chron Obstruct Pulmon Dis. 2020 Feb 12;15:345-355. doi: 10.2147/COPD.S234646. eCollection 2020.
10
Regional lung densities in alpha-1 antitrypsin deficiency compared to predicted values.
Respir Res. 2019 Feb 28;20(1):45. doi: 10.1186/s12931-019-1012-3.

本文引用的文献

1
A population based case-control study of cataract and inhaled corticosteroids.
Br J Ophthalmol. 2003 Oct;87(10):1247-51. doi: 10.1136/bjo.87.10.1247.
2
The relation of body mass index to asthma, chronic bronchitis, and emphysema.
Chest. 2002 Oct;122(4):1256-63. doi: 10.1378/chest.122.4.1256.
5
Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 2002 Sep 1;166(5):680-5. doi: 10.1164/rccm.2112043.
6
Quantitative computed tomography assessment of lung structure and function in pulmonary emphysema.
Eur Respir J. 2001 Oct;18(4):720-30. doi: 10.1183/09031936.01.00255701.
8
Exercise capacity predicts health status in alpha(1)-antitrypsin deficiency.
Am J Respir Crit Care Med. 2001 Mar;163(4):936-41. doi: 10.1164/ajrccm.163.4.2007048.
10
Prognostic value of nutritional status in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 1999 Dec;160(6):1856-61. doi: 10.1164/ajrccm.160.6.9902115.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验